Helixgate

Helixgate

Uncategorized

STAT+: More political interference at the FDA?

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

This is a photo of a young RFK Jr. trying to ride a small rhino. Send news tips and RINO jokes to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.

Former DOGE co-founder v. former state Covid-19 czar

Although most people whom DOGE fired from HHS probably don’t live in Ohio, they may feel a personal connection to the gubernatorial race there.

Continue to STAT+ to read the full story…

Read More

Published

on

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

This is a photo of a young RFK Jr. trying to ride a small rhino. Send news tips and RINO jokes to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.

Former DOGE co-founder v. former state Covid-19 czar

Although most people whom DOGE fired from HHS probably don’t live in Ohio, they may feel a personal connection to the gubernatorial race there.

Continue to STAT+ to read the full story…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

EnGene’s shares crash on updated pivotal bladder cancer data

EnGene’s shares crash on updated pivotal bladder cancer data

Published

on

EnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects.

The Canadian biotech’s shares {$ENGN} fell 80% Thursday morning after reporting …​ ​Read More

Continue Reading

Uncategorized

Angelini to buy Catalyst in $4B play for rare neuro drugs

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.

Read More

Published

on

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.

Read More

Continue Reading

Uncategorized

Angelini inks $4.1B Catalyst buy to enter US rare disease market

Published

on

Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.

Continue Reading
Advertisement

Trending